2013-04-19
Host and Viral Predictors of Response to Antiviral Therapy in Chronic Hepatitis B
Publication
Publication
Voorspellers van respons op behandeling in chronische hepatitis B
Chronic hepatitis B (CHB) is a major cause of liver disease worldwide despite the availability of effective vaccination. There are still more than 350 million people chronically infected with the hepatitis B virus (HBV)1 and progression of HBV-related liver inflammation to cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) is estimated to result in up to 1.2 million deaths annually.
| Additional Metadata | |
|---|---|
| , , , , | |
| Printing of this thesis was supported by F. Hoffmann-La Roche, Erasmus Universiteit Rotterdam, the department of Gastroenterology and Hepatology of the Erasmus MC Rotterdam, Nederlandse Vereniging voor Hepatologie, J.E. Jurriaanse Stichting, Merck, Sharp & Dohme B.V., Gilead Sciences, Innogenetics, Abbott, Boehringer Ingelheim BV and Virology Education B.V. | |
| H.L.A. Janssen (Harry) | |
| Erasmus University Rotterdam | |
| hdl.handle.net/1765/39715 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Sonneveld, M. (2013, April 19). Host and Viral Predictors of Response to Antiviral Therapy in Chronic Hepatitis B . Retrieved from http://hdl.handle.net/1765/39715 |
|
